Business
Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury
Additional Funding to Support Randomized Study Evaluating Earlier Access to INTERCEPT Fibrinogen Complex in Trauma Associated Hemorrhagic Shock Patients
About this update from Cerus Corporation
[{"type":"text","content":"\nAdditional Funding to Support Randomized Study Evaluating Earlier Access to INTERCEPT Fibrinogen Complex in Trauma Associated Hemorrhagic Shock Patients\n\n\n CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq: CERS) announced today that it has been awarded an additional $7.2 million contract amendment by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment (IBAS) program for the development of lyophilized Pathogen Reduced, Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex, or IFC, and, as lyophilized, LyoIFC) to treat bleeding due to trauma. This additional award is additive to the approximately $18 million currently provided for under Cerus’ contract with the DoD to develop a manufacturing capability to provide a room-temperature, shelf-stable LyoIFC for use in austere military environments where refrigeration is limited or not feasible to improve the care of both military and civilian patients with traumatic injury.\n\n\nThe additional funding will support CRYO-FIRST, a randomized study comparing the use of pre-thawed IFC to conventional cryoprecipitated antihemophilic factor (CRYO-AHF) in trauma associated hemorrhagic shock patients.\n\n\n“We are privileged to extend our collaboration with the DoD to gain additional insights on how the immediate availability of IFC can potentially benefit trauma patients with earlier fibrinogen transfusion compared to conventional frozen CRYO-AHF. We believe this study will support and build upon the current broad clinical adoption of IFC by U.S. hospitals,” said Dr. Laurence Corash, Cerus’ founder and chief scientific officer. “In addition, we expect the results of the CRYO-FIRST study could provide critical information about how best to treat acute trauma patients with fibrinogen deficiency and could be directly relevant to future use of LyoIFC.”\n\n\n“We believe LyoIFC represents a next generation product that could help enable the provision of fibrinogen to severely bleeding patients for early treatment pre-hospital and during medical evacuations of wounded warfighters at or near the point of injury as well as at forward surgical hospitals,” continued Dr.Corash. “Hemorrhage is a leading cause of preventable death in trauma patients and by providing fibrinogen as early as possible in the treatment cycle, we beli...